Skip to main content
Equibles
AVBP logo

AVBP · ArriVent BioPharma, Inc.

Track AVBP — free

Use AVBP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AVBP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$29.00 +0.30 (+1.05%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$1.42B
Shares
49.31M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$29.00 Open$29.16 Day$28.15–29.21 52W close$17.17–34.74 Avg vol 30d438K Short int8.7M · 17.6% float · 20.4d Short vol67% Last earningsMay 11, 2026 DataJan 2024–Sep 2026 Filing10-Q · Aug 12

Up next

Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$163.74M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$373.12M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+36.0%
Year over year · more shares
Price change (1Y)
+52.1%
Trailing year
Short interest
17.6%
Latest settlement · 20.4 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +8%
above
Price vs 50-day avg −6%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 67%
mid-range
Momentum
relative strength
Strong
1-month return −3%
trailing
6-month return +32%
trailing
YTD return +44%
this year
Relative strength +14%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $31 › 200d $27 — 50d above 200d
Institutional flow Accumulating
+14% holders QoQ · +35 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
17.63% of float · ▲ +5.6% MoM · 20.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
159 holders — near 2-yr high, broad support
Squeeze score 70
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 58%
annualized · 1-yr
Max drawdown −24%
past year
ATR 4.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+8% Bullish
Price vs 50-day avg
−6% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
67% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $31 › 200d $27 — 50d above 200d
Institutional flow Accumulating
+14% holders QoQ · +35 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
17.63% of float · ▲ +5.6% MoM · 20.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
159 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $17 Now $29 · 67% Range high $35
vs 200-day avg +8% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AVBP
ArriVent BioPharma, Inc.
this stock
$1.42B +44.1% — — 17.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
159
% held
95.5%
Net QoQ
+4.4M sh
Top holder
SUVRETTA CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
143
View
Short & Settlement
Short Interest Rising
Shares short
8.7M
Days to cover
20.4d
Change
+464.3K sh
View
Short Volume
Short vol %
67%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
99
Value
$3.1K
As of
Aug 13, 2026
View
Off-Exchange
Off-exchange %
29.7%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-166.3M
EPS diluted
$-4.32
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 12, 2026
This year
10
View
Exempt Offerings
Offering
$145.0M
Filed
Dec 29, 2022
View
Earnings & Events
Earnings Calls
Last call
May 11, 2026
View

Performance

5D 20D 120D MTD YTD
AVBP -6.5% -3.3% +31.7% -3.5% +44.1%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -5.4% -1.6% +13.9% -3.1% +32.1%
Key facts CIK 1868279 CUSIP 04272N102 13F (30d) 89 filings 89 filers Visit website Investor relations